Key Takeaways:
- Nanoscope Therapeutics has received a new US patent for its Multi-Characteristic Opsin (MCO) technology platform, providing broad protection for methods of using the platform to restore vision in patients with photoreceptor degeneration.
- The MCO platform is a one-time, in-office, intravitreal disease-agnostic therapy designed to restore vision in patients with retinitis pigmentosa, Stargardt disease, and geographic atrophy.
- The patent provides intellectual property protection through 2039, with the potential for additional patent term extension following FDA approval of therapeutic products based on the technology.
- Nanoscope has also secured corresponding patents in Australia and Japan, with patents in China and the EU pending.
- The company has released positive long-term safety results from its EXTEND study and positive 3-year follow-up data from its REMAIN study, demonstrating the safety and efficacy of the MCO-010 treatment.
Introduction to Nanoscope’s MCO Technology
Nanoscope Therapeutics has been granted a new patent (US Patent No. 12459977) from the US Patent and Trademark Office (USPTO) for its Multi-Characteristic Opsin (MCO) technology platform. This platform is a novel and innovative synthetic opsin for optogenetic modulation, designed to restore vision in patients with photoreceptor degeneration, including retinitis pigmentosa (RP), Stargardt disease (SD), and geographic atrophy (GA). The MCO platform is a one-time, in-office, intravitreal disease-agnostic therapy that utilizes the remaining visual circuitry following photoreceptor death by activating highly dense bipolar retinal cells to become light sensitive.
Patent Protection and Intellectual Property
The new patent provides broad protection for methods of using the MCO platform to restore vision in patients who have lost photoreceptors due to retinal degenerative diseases. With the patent, intellectual property protection is granted through 2039, with the potential for additional patent term extension following FDA approval of therapeutic products based on the technology. This patent milestone reinforces the strategic value of the MCO platform as a durable, first-in-class technology with broad clinical and commercial potential. Nanoscope has also secured corresponding patents in Australia and Japan, with patents in China and the EU pending, further solidifying its intellectual property position.
Clinical Trials and Study Results
Recently, Nanoscope released positive long-term safety results from its EXTEND study, a 5-year follow-up of participants who received a single intravitreal injection of MCO-010 in a previously conducted phase 1/2a2 trial. The results showed that a single intravitreal injection of MCO-010 is safe and well-tolerated over 5 years, with no serious adverse effects or new safety signals. The safety profile of MCO-010 remained consistent between the phase 1/2a trial and the long-term follow-up period. Additionally, the company released positive 3-year follow-up data from its REMAIN study, the long-term extension of the phase 2b/3 RESTORE trial evaluating MCO-010 in retinitis pigmentosa (RP). The results showed patients maintained an average best corrected visual acuity (BCVA) gain from baseline of approximately 0.3 LogMAR through week 152.
Significance and Future Directions
The patent and study results demonstrate the potential of the MCO platform to restore vision in patients with photoreceptor degeneration. The broad protection provided by the patent and the positive clinical trial results position Nanoscope Therapeutics for future success in the development of treatments for retinal degenerative diseases. With the patent providing intellectual property protection through 2039, the company has a strong foundation for its pipeline, extending market exclusivity, enhancing competitive barriers, and supporting multiple future indications built on a single, scalable optogenetic platform. As the company continues to advance its MCO platform, it is likely to remain a key player in the development of innovative treatments for vision restoration.
Conclusion
In conclusion, Nanoscope Therapeutics has made significant progress in the development of its MCO technology platform, with the receipt of a new US patent and positive clinical trial results. The patent provides broad protection for the platform, and the study results demonstrate its safety and efficacy in restoring vision in patients with photoreceptor degeneration. With a strong intellectual property position and a promising pipeline, Nanoscope Therapeutics is well-positioned for future success in the development of treatments for retinal degenerative diseases. As the company continues to advance its MCO platform, it is likely to have a significant impact on the field of vision restoration and improve the lives of patients with photoreceptor degeneration.